Search

Anne Marie Sabrina Wehbe

Examiner (ID: 18312)

Most Active Art Unit
1633
Art Unit(s)
1632, 1633, 1634
Total Applications
1342
Issued Applications
603
Pending Applications
239
Abandoned Applications
542

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16086941 [patent_doc_number] => 20200197457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS [patent_app_type] => utility [patent_app_number] => 16/725485 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725485 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/725485
Oncolytic virus for expression of immune checkpoint modulators Dec 22, 2019 Issued
Array ( [id] => 15931079 [patent_doc_number] => 20200157173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/715077 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715077 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/715077
CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE Dec 15, 2019 Abandoned
Array ( [id] => 15676885 [patent_doc_number] => 20200093106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI [patent_app_type] => utility [patent_app_number] => 16/703116 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16703116 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/703116
Humanized non-human animals with restricted immunoglobulin heavy chain loci Dec 3, 2019 Issued
Array ( [id] => 15590331 [patent_doc_number] => 20200071700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES [patent_app_type] => utility [patent_app_number] => 16/687501 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687501 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/687501
COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES Nov 17, 2019 Abandoned
Array ( [id] => 17937067 [patent_doc_number] => 11471499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia [patent_app_type] => utility [patent_app_number] => 16/684241 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 41 [patent_no_of_words] => 23208 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684241 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/684241
Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia Nov 13, 2019 Issued
Array ( [id] => 17385929 [patent_doc_number] => 20220033781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/626816 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50507 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626816 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/626816
ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF Nov 11, 2019 Abandoned
Array ( [id] => 17292235 [patent_doc_number] => 20210388074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => HUMANIZED AND VARIANT TGF-BETA3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/290834 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290834 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/290834
HUMANIZED AND VARIANT TGF-BETA3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF Nov 3, 2019 Pending
Array ( [id] => 17292277 [patent_doc_number] => 20210388116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 17/290843 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290843 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/290843
Compositions and methods for diagnosis of cardiovascular disease Oct 31, 2019 Issued
Array ( [id] => 17292277 [patent_doc_number] => 20210388116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 17/290843 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290843 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/290843
Compositions and methods for diagnosis of cardiovascular disease Oct 31, 2019 Issued
Array ( [id] => 17292277 [patent_doc_number] => 20210388116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 17/290843 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290843 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/290843
Compositions and methods for diagnosis of cardiovascular disease Oct 31, 2019 Issued
Array ( [id] => 15553419 [patent_doc_number] => 20200061121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => Non-invasive in vivo imaging and methods for treating type I diabetes [patent_app_type] => utility [patent_app_number] => 16/669840 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669840 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/669840
Non-invasive in vivo imaging and methods for treating type I diabetes Oct 30, 2019 Abandoned
Array ( [id] => 15963753 [patent_doc_number] => 20200165628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => TISSUE SELECTIVE TRANSGENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/670996 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670996 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/670996
TISSUE SELECTIVE TRANSGENE EXPRESSION Oct 30, 2019 Abandoned
Array ( [id] => 16619988 [patent_doc_number] => 20210038641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Method for Producing an Exosome Containing Agent for Metastasis Suppression [patent_app_type] => utility [patent_app_number] => 16/668581 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668581 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/668581
Method for Producing an Exosome Containing Agent for Metastasis Suppression Oct 29, 2019 Abandoned
Array ( [id] => 16619988 [patent_doc_number] => 20210038641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Method for Producing an Exosome Containing Agent for Metastasis Suppression [patent_app_type] => utility [patent_app_number] => 16/668581 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668581 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/668581
Method for Producing an Exosome Containing Agent for Metastasis Suppression Oct 29, 2019 Abandoned
Array ( [id] => 19737215 [patent_doc_number] => 12214023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Compositions and methods for expressing factor IX [patent_app_type] => utility [patent_app_number] => 16/657961 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 39 [patent_no_of_words] => 47676 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657961 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/657961
Compositions and methods for expressing factor IX Oct 17, 2019 Issued
Array ( [id] => 19961832 [patent_doc_number] => 12331320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Genome edited cancer cell vaccines [patent_app_type] => utility [patent_app_number] => 16/596829 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 67 [patent_no_of_words] => 24831 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596829 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/596829
Genome edited cancer cell vaccines Oct 8, 2019 Issued
Array ( [id] => 19961832 [patent_doc_number] => 12331320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Genome edited cancer cell vaccines [patent_app_type] => utility [patent_app_number] => 16/596829 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 67 [patent_no_of_words] => 24831 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596829 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/596829
Genome edited cancer cell vaccines Oct 8, 2019 Issued
Array ( [id] => 15676883 [patent_doc_number] => 20200093105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => Genetically Modified Non-Human Animals And Methods Of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/586573 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586573 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/586573
Genetically modified non-human animals and methods of use thereof Sep 26, 2019 Issued
Array ( [id] => 17399623 [patent_doc_number] => 20220041713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => TARGETED IMMUNOTOLERANCE [patent_app_type] => utility [patent_app_number] => 17/277008 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277008 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/277008
TARGETED IMMUNOTOLERANCE Sep 17, 2019 Abandoned
Array ( [id] => 16549971 [patent_doc_number] => 10883120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => DNA plasmids for the fast generation of homologous recombination vectors for cell line development [patent_app_type] => utility [patent_app_number] => 16/568771 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 15865 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568771 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/568771
DNA plasmids for the fast generation of homologous recombination vectors for cell line development Sep 11, 2019 Issued
Menu